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Abstract The treatment and control of opisthorchiasis
relies on a single drug, praziquantel; hence, there is a need
to develop novel opisthorchicidal drugs. We investigated
the in vitro and in vivo activity of the antimalarial
mefloquine against Opisthorchis viverrini. Hamsters
infected with O. viverrini for 2 weeks (juvenile infections)
and 4 weeks (adult infections) were treated orally with
single 200–400-mg/kg oral mefloquine. Worm burden
reductions were assessed against untreated control ham-
sters. Worms were incubated in the presence of 10 and
100 µg/ml mefloquine. Scanning electron microscopy was
used to examine adult O. viverrini after recovery from
hamsters and following in vitro incubation. A single oral
dose of 300-mg/kg mefloquine resulted in worm burden
reductions of 88.5% (juvenile infection) and 96.0% (adult
infections), respectively. Incubation with 10 and 100 µg/ml
mefloquine resulted in rapid death of O. viverrini. Exten-
sive tegumental disruption such as blebbing, sloughing, and
furrowing was seen on worms incubated in vitro and on
flukes recovered 48 h posttreatment. In conclusion, we have
documented promising opisthorchicidal activities in ham-
sters and in vitro with the tegument being an important drug
target. Proof-of-concept studies with mefloquine could be
considered in opisthorchiasis patients.
Introduction
Opisthorchiasis is endemic in Cambodia and Vietnam and is a
major public health problem in Thailand and Lao People’s
Democratic Republic. It is estimated that 67.3 million people
are at risk and nine million are infected (Keiser and Utzinger
2007). Caused by the liver fluke Opisthorchis viverrini, the
disease is associated with abdominal and hepatobiliary
symptoms. Serious manifestations such as obstructive
jaundice and ascending cholangitis are observed (Mairiang
and Mairiang 2003; Sithiathaworn et al. 2009). Chronic
infections are associated with cholangiocarcinoma, the ma-
lignant bile duct cancer (Honjo et al. 2005; Sripa et al. 2007;
Sripa and Pairojkul 2008).
Praziquantel is the drug of choice for treating infections
with O. viverrini. Single-dose treatment with praziquantel is
highly effective, causes few adverse events, and is cheap
(Keiser and Utzinger 2004; Sithiathaworn et al. 2007).
Treatment failures of praziquantel in O. viverrini-infected
patients have not yet been reported. Nonetheless, with
increasing drug usage in large-scale mass treatment
programs in O. viverrini endemic settings (Montresor et
al. 2008), praziquantel-resistant isolates might develop. It is
therefore dangerous to rely on a single drug for treatment
and control of this neglected tropical disease.
An often successful fast-track approach to develop
novel drugs for tropical diseases is to piggyback on
Parasitol Res (2009) 105:261–266
DOI 10.1007/s00436-009-1395-z
J. Keiser (*)
Department of Medical Parasitology and Infection Biology,
Swiss Tropical Institute,
P.O. Box, 4002 Basel, Switzerland
e-mail: jennifer.keiser@unibas.ch
P. Odermatt
Department of Public Health and Epidemiology,
Swiss Tropical Institute,
P.O. Box, 4002 Basel, Switzerland
S. Tesana
Department of Parasitology, Faculty of Medicine,
Khon Kaen University,
Khon Kaen, Thailand
marketed drugs, for which a wealth of clinical informa-
tion is already available, hence, which would not need
to undergo the long and expensive process of drug
development (Nwaka and Hudson 2006). Following this
strategy, we have already documented the opisthorchicidal
properties of the antimalarials artemether and artesunate
(Keiser et al. 2006) and the Chinese anthelmintic
tribendimidine in the O. viverrini hamster model (Keiser
et al. 2008).
The aim of the present work was to investigate the
activity of mefloquine against O. viverrini. We have
recently reported that this drug, widely and effectively
used in the treatment and prophylaxis of malaria, is highly
effective against schistosomes, the related blood flukes:
high worm burden reductions were achieved in mice
infected with Schistosoma mansoni and Schistosoma
japonicum and treated with single oral doses of mefloquine
(Keiser et al. 2009). In the present study, we evaluate the
dose–response relationship of oral mefloquine administered
to hamsters infected with adult O. viverrini. The minimal
effective mefloquine dose in adult O. viverrini-infected
hamsters was tested in a next step against juvenile
O. viverrini in vivo. Finally, we assessed tegumental
alterations in adult O. viverrini recovered from hamsters
following mefloquine treatment and in worms incubated with
mefloquine in vitro using a scanning electron microscope
(SEM).
Materials and methods
Mefloquine
Mefloquine was kindly provided by Mepha (Aesch,
Switzerland). We prepared a homogenous suspension in
7% Tween-80 and 3% ethanol before oral administration.
Ethical clearance and O. viverrini hamster model
All animal studies presented here were approved by the
local government according to Swiss national regulations.
Metacercariae of O. viverrini were obtained from
cyprinid fish caught in Khon Kaen province, Thailand, as
described previously (Keiser et al. 2006).
Twenty-seven male Syrian Gold hamsters (age 3 weeks,
weight ∼100 g) were purchased from Charles River
(Sulzfeld, Germany). Hamsters were kept in groups of
four in environmentally controlled conditions (temperature
∼25°C; humidity ∼70%; 12-h light and 12-h dark cycle).
Hamsters had free access to water and rodent diet. The
hamsters were each infected intragastrically with 45
O. viverrini metacercariae.
Dose–response relationship of mefloquine against adult
O. viverrini
Four weeks postinfection groups of four hamsters were
treated orally with single doses of 200–400-mg/kg doses
of mefloquine. Four untreated infected hamsters served as
control. Hamsters were killed and dissected 10 days
posttreatment. All O. viverrini were removed from the gall
bladder and bile ducts and counted.
Effect of mefloquine on juvenile O. viverrini
Four hamsters were treated with a single oral dose of
300 mg/kg mefloquine at day 14 postinfection. An infected
but untreated group of four hamsters served as controls. On
day 32 postinfection hamsters were killed; the livers were
removed and all flukes present in the bile ducts and gall
bladder were counted.
Statistical analysis
The Kruskal–Wallis test (KW) was used to compare the
medians of the treatment and control groups at a significance
level of 5%. Statsdirect statistical software (version 2.7.2,
Statsdirect Ltd., Cheshire, UK) was used for the statistical
analysis.
In vivo SEM observations
Three hamsters were treated with single oral 300 mg/kg
mefloquine 5 weeks postinfection. After 24, 48, and 72 h
posttreatment, one hamster each was killed by CO2, and
flukes were collected from the gall bladder and bile ducts.
O. viverrini collected from one hamster, which had not
been treated, served as control specimens. The flukes were
rinsed in 0.9% (v/v) saline and fixed with 2.5% glutaralde-
hyde in a phosphate-buffered saline buffer for 24 h at room
temperature. Following fixation, O. viverrini were dehy-
drated and critically point-dried (Bomar SPC-900; Tacoma,
USA). After mounting the trematodes on aluminum stubs,
they were sputter-coated with gold of 20 nm (Baltec Med
020; Tucson, USA) and observed in a high-resolution SEM
(Philips XL30 ESEM; Eindhoven, The Netherlands) at an
accelerating voltage of 5 kV.
In vitro SEM observations
O. viverrini collected from untreated hamsters were
incubated in 2-ml minimal essential medium (MEM;
Invitrogen, Carlsbad, USA) in the presence of 10 and
100 µg/ml mefloquine. Control flukes were incubated in
MEM in the absence of drug. Cultures were kept at 37°C in
an atmosphere of 5% CO2 and observed after 1 h of
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exposure under a dissecting microscope. Subsequently, all
flukes were collected and processed for SEM as described
above.
Results
Dose–response relationship of mefloquine against adult
O. viverrini
In Table 1, we present the dose–response relationship of
mefloquine against adult O. viverrini harbored in hamsters.
At the lowest dose investigated (200-mg/kg), no effect
on the worm burden was observed. A worm burden
reduction of 96% was found when a 300-mg/kg single oral
dose of mefloquine was administered to hamsters. The
highest dose administered (400-mg/kg) achieved a complete
elimination of worms. The mean worm burden observed in
untreated control hamsters was 12.5 worms. There was a
significant difference (KW=3.86, P=0.049) in the medians
of the total worm burden between treated and untreated
hamsters.
Effect of mefloquine on juvenile O. viverrini in hamsters
The effect of a 300-mg/kg single oral dose of mefloquine
against juvenile O. viverrini is summarized in Table 1. At
this dose, a worm burden reduction of 88.5% was obtained,
which was statistically significant (KW=5.39, P=0.02). In
this experiment, the control group harbored a mean of 6.5
O. viverrini.
SEM observations of control O. viverrini
The tegument of adult O. viverrini obtained from untreated
hamsters had a normal appearance. In Fig. 1, the oral sucker
is presented and in Fig. 2 the anterior part of an adult
O. viverrini is shown.
In vivo SEM investigations
Seven worms were recovered from a hamster 24 h after
treatment with a single 300-mg/kg oral dose of mefloquine.
These flukes had a normal appearance and showed active
movements. SEM observations of these flukes revealed no
damage of the tegument (no picture shown).
Forty-eight hours after drug administration, ten worms
were removed from a hamster’s bile duct. The worms
appeared pale and were inactive. Substantial damage on the
ventral and dorsal tegument as well as on the anterior and
posterior regions of the trematodes was visible on eight
flukes by means of SEM. Two worms revealed no damage.
Extensive sloughing was seen near the oral and ventral
suckers (Figs. 3 and 4) and the ventral and dorsal anterior
and posterior surfaces (Fig. 5). Blebbing was visible on the
entire surfaces and the oral and ventral suckers (Figs. 3 and 4).
Extensive furrowing was visible on the ventral and dorsal
surfaces (Figs. 3, 4, and 5). One fluke showed a severely
sloughed and collapsed tegument leading to structural
disorganization (Fig. 6).
Seventy-two hours following treatment with mefloquine,
the majority of flukes had been expelled and only three
O. viverrini were recovered from the bile duct of the one
hamster designated at this time point. All O. viverrini were
alive but showed reduced mobility. Tegumental damage of
these flukes was less severe than observed at the 48-h time
point. Small areas of sloughing and blebbing were observed
on all flukes at the dorsal or ventral surfaces (no images
shown).
In vitro SEM observations
All O. viverrini had died 1 h after incubation in the
presence of 10 and 100 µg/ml of mefloquine. Extensive
tegumental alterations were observed by SEM. Worms
exposed to 10 µg/ml of mefloquine showed severe blebbing
on the entire body surface area (Figs. 7 and 8). Swelling of
Table 1 Effect of mefloquine against adult and juvenile O. viverrini
Stage of
infection
Treatment Dose
(mg/kg)
No. of
hamsters
investigated
No. of hamsters
cured
Mean worm
burden (SD)
Total worm burden
reduction (%)
Kruskal–Wallis P value
Adult
infection
Control – 4 0 12.5 (5.8) – – –
Mefloquine 400 4 4 0 100 3.85 0.049
300 4 3 0.5 (1.0) 96.0
200 4 0 14.0 (4.1) 0
Juvenile
infection
Control 4 0 6.5 (3.1) –
Mefloquine 300 4 2 0.75 (0.96) 88.5 5.39 0.02
SD standard deviation
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the tegument was evident on the dorsal and ventral surfaces
(Fig. 7). O. viverrini incubated with 100 µg/ml showed
sloughing and the midbody regions of several flukes were
carpeted in blebs (no picture shown). The anterior parts of
the worms were highly affected, revealing a badly disrupted
tegument. The tegumental apex of several worms had been
removed from the anterior half of the flukes, exposing the
basal lamina (Figs. 9 and 10).
Discussion
To our knowledge, we have documented for the first time
that the antimalarial drug mefloquine possesses interesting
opisthorchicidal properties in hamsters. Single oral doses
of 300-mg/kg of mefloquine resulted in worm burden
reductions of 88.5% (juvenile infections) and 96% (adult
infections), respectively. In addition, O. viverrini incubated
with 10 and 100 µg/ml mefloquine in vitro died rapidly.
Promising activities of the antimalarial mefloquine
against biologically related trematodes, the schistosomes,
have been described recently: diminished egg fecundity
was observed in mice treated with a low dose of mefloquine
(150-mg/kg; Van Nassauw et al. 2008). At a dose of 400-
mg/kg, complete or very high total and female worm
burden reductions were observed against adult and juvenile
stages of S. mansoni and S. japonicum (Keiser et al. 2009).
Morphological studies on adult S. japonicum worms
following mefloquine treatment showed a pronounced
dilatation of the gut, accompanied by focal or extensive
peeling of gut epithelial cells or even focal collapse of the
gut wall as well as swelling of tegument, muscles, or even
parenchymal tissues (Zhang et al. 2009). Finally, SEM
studies on S. mansoni following mefloquine administration
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Fig. 3 SEM of an adult
O. viverrini 48 h after the ad-
ministration of a single dose of
mefloquine (400-mg/kg) showing
furrowing (f), sloughing (s), and
blebbing (b) of the tegument near
the oral sucker (OS)
Fig. 4 SEM of an adult
O. viverrini 48 h after the
administration of a single dose of
mefloquine (400-mg/kg) with
furrowing (f), blebbing (b), and
sloughing (s) near the ventral
sucker (VS) visible
Fig. 5 SEM of an adult
O. viverrini 48 h after the
administration of a single dose
of mefloquine (400-mg/kg)
showing furrowing (f) and
sloughing (s) on the ventral tail
region
Fig. 6 SEM of an adult O.
viverrini 48 h after the adminis-
tration of a single dose of
mefloquine (400-mg/kg)
depicting a collapsed anterior
region of the fluke
1 2
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Fig. 1 SEM of the oral sucker
(OS) and tegument with papillae
(P) of an adult O. viverrini
removed from an untreated
control hamster
Fig. 2 SEM of the oral sucker
(OS), ventral sucker (VS), and
tegument with papillae (P) of an
adult O. viverrini removed from
an untreated control hamster
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in vivo and incubation with mefloquine in vitro showed that
the tegument seems to be a main drug target as extensive
tegumental disruption was observed (Manneck et al.,
submitted for publication).
Interestingly, the liver flukes Fasciola hepatica and
Clonorchis sinensis harbored in rats are not affected by
mefloquine, even when high dosages are used (unpublished
observations).
Our SEM study revealed severe tegumental alterations as
sloughing, furrowing, and blebbing, which occurred rapidly
following incubation of O. viverrini with mefloquine in vitro.
In several flukes, the tegument had been sloughed off
exposing the basal membrane. Interestingly, both O. viverrini
as well as S. mansoni (Manneck et al., submitted for
publication) incubated with mefloquine die in the absence
of red blood cells or hemin in vitro; thus, an interference
with the hemoglobin digestion, the supposed mode of action
against Plasmodium sp. (Brocks and Mehvar 2003), might
not be the sole mechanism of action of mefloquine against
trematodes.
A slower onset of action was observed when
mefloquine was administered to O. viverrini-infected
hamsters. Tegumental alterations on O. viverrini were first
detected 48 h posttreatment with mefloquine. All surfaces
and both the anterior and posterior part of the flukes were
affected, with similar tegumental alterations observed
when compared to the in vitro incubation of Opisthorchis
with mefloquine. A slow onset of action was also
observed on the tegument of S. mansoni collected from
mice posttreatment with mefloquine (Manneck et al.,
submitted for publication). Interestingly, tegumental
changes did not increase further in severity; in contrast,
less damage was observed on O. viverrini collected 72 h
posttreatment from hamsters when compared to the 48-h time
point. However, affected O. viverrini might have already
been eliminated at this time point. The differences
between the fast drug action on O. viverrini in vitro and
the slower action in vivo cannot be explained at the
moment; however, drug concentrations are most likely
much lower in the hamster bile ducts when compared to
the in vitro concentrations used.
The mechanism of how O. viverrini are attacked by
praziquantel seems to be different from mefloquine:
extensive blebbing was also observed when O. viverrini
were incubated with praziquantel in vitro. However, a
disruption of the vacuoles resulting in crater-like lesions
was a common feature seen on the tegument of O.
viverrini incubated with praziquantel (Apinhasmit and
Sobhon 1996; Mehlhorn et al. 1983; Sirisinha et al. 1984).
Both the ventral as well as the dorsal tegument were
affected by praziquantel treatment, whereas the anterior
parts of the worms tended to be damaged less than the
posterior parts. Similar tegumental changes were observed
when worms were collected following praziquantel treat-
ment in vivo. Tegumental damage was observed already
4 h posttreatment of hamsters with praziquantel (Sirisinha
et al. 1984), thus much earlier when compared to
mefloquine.
10
7
9
8
VS
b
b
OS
OS
f
sw
Fig. 7 SEM of an adult
O. viverrini 1 h after the incuba-
tion with 10 µg/ml mefloquine.
Blebbing (b) and swelling (sw)
observed on the oral sucker
(OS) region
Fig. 8 SEM of the dorsal
midbody region of an adult
O. viverrini 1 h after the incuba-
tion with 10 µg/ml mefloquine.
Extensive blebbing (b) visible
Fig. 9 SEM of an adult
O. viverrini 1 h after the incuba-
tion with 100 µg/ml mefloquine.
Extensive disruption of the
tegument near the ventral
sucker (VS)
Fig. 10 SEM of the oral sucker
(OS) region of an adult
O. viverrini 1 h after the incuba-
tion with 100 µg/ml mefloquine.
The tegument has been sloughed
off, exposing the basal lamina
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Another drug which was recently analyzed for its
opisthorchicidal properties is the Chinese anthelmintic drug
tribendimidine (Keiser et al. 2008). In contrast to meflo-
quine and praziquantel, SEM analysis of O. viverrini
incubated in vitro showed only mild damage of the
tegument. A complete closure of the oral sucker was a
common feature observed on O. viverrini recovered
posttreatment of hamsters with tribendimidine. Additional
tegumental alterations seen were sloughing, furrowing, and
blebbing. Similar to mefloquine-treated specimens in vivo,
no clear dorsal–ventral and anterior–posterior difference in
tegument disruption was evident for O. viverrini exposed to
tribendimidine and the severity of damage did not increase
further at 48–72 h posttreatment (Keiser et al. 2008).
Hence, SEM observations made on O. viverrini collected
from mefloquine-, praziquantel-, and tribendimidine-treated
hamsters point to different mechanisms of actions. Drug
combinations, characterized by independent modes of
action, are in many therapeutic areas seen as a possibility
to enhance efficacy while ensuring mutual protection
against resistance. An evaluation of the potential of
combinations of mefloquine, praziquantel, and tribendimi-
dine in O. viverrini-infected hamsters has been initiated in
our laboratories.
In conclusion, we have strengthened the current evi-
dence base of the interesting trematocidal properties of
mefloquine documenting promising opisthorchicidal activ-
ities in hamsters and in vitro. The tegument of O. viverrini
seems to be a potential drug target of this antimalarial drug.
Proof-of-concept studies, which have already been
launched in African settings to assess the effect of
mefloquine in infections with S. mansoni and Schistosoma
haematobium, could also be considered in opisthorchiasis
patients.
Acknowledgement We thank Mrs. Mireille Vargas for her help with
the in vivo and in vitro studies and Mr. Gianni Morson and Mrs. Evi
Bieler at the Center for Microscopy at the University of Basel for their
expert help with the SEM studies. J. Keiser (project no. PPOOA-
114941) and P. Odermatt (project no. NF3270B0-110020) are grateful
to the Swiss National Science Foundation and the Swiss Agency for
Development and Cooperation for financial support.
References
Apinhasmit W, Sobhon P (1996) Opisthorchis viverrini: effect of
praziquantel on the adult tegument. Southeast Asian J Trop Med
Public Health 27:304–311
Brocks DR, Mehvar R (2003) Stereoselectivity in the pharmacody-
namics and pharmacokinetics of the chiral antimalarial drugs.
Clin Pharmacokinet 42:1359–1382
Honjo S, Srivatanakul P, Sriplung H, Kikukawa H, Hanai S, Uchida
K, Todoroki T, Jedpiyawongse A, Kittiwatanachot P, Sripa B,
Deerasamee S, Miwa M (2005) Genetic and environmental
determinants of risk for cholangiocarcinoma via Opisthorchis
viverrini in a densely infested area in Nakhon Phanom, northeast
Thailand. Int J Cancer 117:854–860
Keiser J, Utzinger J (2004) Chemotherapy for major food-borne
trematodes: a review. Exp Opin Pharmacother 5:1711–1726
Keiser J, Utzinger J (2007) Food-borne trematodiasis: current
chemotherapy and advances with artemisinins and synthetic
trioxolanes. Trends Parasitol 23:555–562
Keiser J, Xiao SH, Xue J, Chang ZS, Odermatt P, Tesana S, Tanner M,
Utzinger J (2006) Effect of artesunate and artemether against
Clonorchis sinensis and Opisthorchis viverrini in rodent models.
Int J Antimicrob Agents 28:370–373
Keiser J, Utzinger J, Xiao SH, Odermatt P, Tesana S (2008)
Opisthorchis viverrini: efficacy and tegumental alterations fol-
lowing administration of tribendimidine in vivo and in vitro.
Parasitol Res 102:771–776
Keiser J, Chollet J, Xiao SH, Mei JY, Jiao PY, Utzinger J, Tanner M
(2009) Mefloquine—an aminoalcohol with promising antischis-
tosomal properties in mice. PLoS Negl Trop Dis 3:e350
Mairiang E, Mairiang P (2003) Clinical manifestation of opisthorch-
iasis and treatment. Acta Trop 88:221–227
Mehlhorn H, Kojima S, Rim HJ, Ruenwongsa P, Andrews P, Thomas
H, Bunnag B (1983) Ultrastructural investigations on the effects of
praziquantel on human trematodes from Asia: Clonorchis sinensis,
Metagonimus yokogawai, Opisthorchis viverrini, Paragonimus
westermani and Schistosoma japonicum. Arzneimittelforschung
33:91–98
Montresor A, Cong DT, Sinuon M, Tsuyuoka R, Chanthavisouk C,
Strandgaard H, Velayudhan R, Capuano CM, Le Anh T, Tee Dato
AS (2008) Large-scale preventive chemotherapy for the control
of helminth infection in Western pacific countries: six years later.
PLoS Negl Trop Dis 2:e278
Nwaka S, Hudson A (2006) Innovative lead discovery strategies for
tropical diseases. Nat Rev Drug Discov 5:941–955
Sirisinha S, Puengtomwatanakul S, Sobhon P, Saitongdee P,Wongpayabal
P, Mitranonde V, Radomyos P, Bunnag D, Harinasuta T (1984)
Alterations of the surface tegument ofOpisthorchis viverrini exposed
to praziquantel in vitro and in vivo. Southeast Asian J Trop Med
Public Health 15:95–103
Sithiathaworn P, Yongvanit P, Tesana S, Pairojkul C (2007) Liver
flukes. In: Murrell KD, Fried B (eds) Food-borne parasitic
zoonoses. Springer, New York, pp 3–52
Sithiathaworn P, Sripa B, Kaewkes S, Haswell-Elkins M (2009) Food-
borne trematodes. In: Cook G, Zumla A (eds) Manson’s tropical
diseases, 22nd edn. Saunders, London, pp 1461–1476
Sripa B, Pairojkul C (2008) Cholangiocarcinoma: lessons from
Thailand. Curr Opin Gastroenterol 24:349–356
Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M,
Pairojkul C, Bhudhisawasdi V, Tesana S, Thinkamrop B,
Bethony JM, Loukas A, Brindley PJ (2007) Liver fluke induces
cholangiocarcinoma. PLoS Med 4:e201
Van Nassauw L, Toovey S, Van Op den Bosch J, Timmermans J-P,
Vercruysse J (2008) Schistosomicidal activity of the antimalarial
drug, mefloquine, in Schistosoma mansoni-infected mice. Travel
Med Infect Dis 6:253–258
Zhang CW, Xiao SH, Utzinger J, Chollet J, Keiser J, Tanner M (2009)
Histopathological changes in adult Schistosoma japonicum
harbored in mice treated with a single dose of mefloquine.
Parasitol Res. doi: 10.1007/s00436-009-1341-0
266 Parasitol Res (2009) 105:261–266
